Sutro Biopharma gains nearly double after announcing worldwide strategic collaboration with Astellas Pharma
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Börse:
15,273€
1,31%
Echtzeit-Aktienkurs Astellas Pharma Inc.
Bid:
15,190€
Ask:
15,355€
Nachrichten zur Astellas Pharma Inc. Aktie
Astellas, Sutro Collaborate To Advance Novel Immunostimulatory Antibody-Drug Conjugates
BEIJING (dpa-AFX) - Astellas Pharma Inc. and Sutro Biopharma Inc. (STRO) announced a worldwide, strategic collaboration and licensing agreement focused…
Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas
Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas...…
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for…
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for…
Astellas gene replacement therapy trial put on hold by FDA after nerve issue in patient
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
TOKYO, June 26, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that…
Astellas Pharma Submits Fezolinetant NDA To FDA
TOKYO (dpa-AFX) - Astellas Pharma Inc. said that it has submitted new drug application for fezolinetant to the U.S. Food…
Astellas Submits Fezolinetant New Drug Application to U.S. FDA
Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO, June 23, 2022 /PRNewswire/ -- Astellas…
GlobalStem Cell Therapy Markets Research Report 2022-2031 Featuring Major Players - Anterogen; JCR Pharmaceuticals; Medipost; Osiris Therapeutics; Pharmicell; Astellas Pharma; Cellectis; Celyad
DUBLIN, June 21, 2022 /PRNewswire/ -- The "Stem Cell Therapy Global Market Report 2022: By Type, By Cell, By Application,…
Astellas unit to pay $20.5M upfront to GO Therapeutics in collaboration to discover cancer therapies
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Interstitial Cystitis Drugs Market - 36% of Growth to Originate from North America| Evolving Opportunities with Astellas Pharma Inc. & Bayer AG | 17000+ Technavio Reports
NEW YORK, June 1, 2022 /PRNewswire/ -- The "Interstitial Cystitis Drugs Market by Type (Oral therapy and Intravesical therapy) and…
Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology
- Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- Astellas Pharma Inc.…
Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress
Abstracts represent exciting research progress across four cancers where patients have limited treatment options TOKYO, May 12, 2022 /PRNewswire/ --…
Astellas to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Trial of Fezolinetant in Oral Session at the American College of Obstetricians and Gynecologists Annual Meeting
Astellas investigational nonhormonal treatment meets all primary endpoints, significantly reducing the frequency and severity of vasomotor symptoms associated with menopause…
Astellas Pharma FY21 Core Profit Decreases; Revenue Up 3.7%
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) reported that its fiscal 2021 core operating profit decreased by 2.6% year-on-year…
University Of Tokyo, Astellas Pharma Enter Second Phase Of Collaboration
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced the company and the University of Tokyo have entered the second…
University of Tokyo, Astellas Enter Second Phase of Strategic Partnership for Co-creation of Innovative New Medicines and Medical Solutions
TOKYO, April 25, 2022 /PRNewswire/ -- The University of Tokyo (President: Teruo Fujii, Ph.D.) and Astellas Pharma Inc. (TSE: 4503,…
USD 30.23 billion growth expected in Non-Small Cell Lung Cancer Drugs Market | Evolving Opportunities with AbbVie Inc. and Amgen Inc. | Technavio
NEW YORK, April 20, 2022 /PRNewswire/ -- The global non-small cell lung cancer drugs market size is expected to increase…
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
- Enfortumab vedotin is the first medicine approved in the EU for patients who received a prior platinum-containing chemotherapy and…
Globale Pharmaunternehmen unterstützen Turn Biotechnologies bei der Weiterentwicklung seines Zellverjüngungsprogramms
Turn Biotechnologies, Inc.: Mountain View, Kalifornien (ots/PRNewswire) - Daewoong Pharmaceutical und HanAll Biopharma beteiligen sich gemeinsam mit Astellas Venture Management…
CYTOO-Partner Astellas Gene Therapies hat die Ergebnisse einer AGT/CYTOO-Kooperation zur Auswahl klinischer Kandidaten für die Behandlung von DMD auf dem zweiten Gentherapie-Gipfel für Muskelkrankheiten vorgestellt
GRENOBLE, Frankreich--(BUSINESS WIRE)--CYTOO und Astellas Gene Therapies (AGT) sind im Jahr 2020 eine Forschungskooperation eingegangen, um den klinischen AAV-Gentherapie-Kandidaten von…
Astellas hot flashes treatment fezolinetant fails in late-stage study in Asia
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Astellas: Phase 3 Study Of Fezolinetant On VMS Associated With Menopause Did Not Show Efficacy
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said that 12-week data from phase 3 MOONLIGHT 1 study of fezolinetant…
Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Women in Asia
Astellas MOONLIGHT 1TM clinical trial evaluating investigational fezolinetant 30 mg administered once daily TOKYO, March 14, 2022 /PRNewswire/ -- Astellas…
Central Nervous System (CNS) Stimulant Drugs Market to grow at a CAGR of 5.74 by 2026 | Rise in CNS Disorders to Boost Growth | 17000+ Technavio Reports
NEW YORK, March 14, 2022 /PRNewswire/ -- The central nervous system (CNS) stimulant drugs market is fragmented and the vendors…
Genetic Leap and Astellas Establish Research Collaboration to Develop RNA-targeted Small Molecules for Oncology Target
NEW YORK, March 10, 2022 /PRNewswire/ -- Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to…
Astellas Worth A Look On Revenue Re-Acceleration Potential
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause
TOKYO, March 7, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…
Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
TOKYO and BOTHELL, Wash., Feb. 14, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas")…
Astellas Pharma Inc. 2021 Q3 - Results - Earnings Call Presentation
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Astellas Pharma Announces Positive Data From Study Of AT845 In Adults With Late-Onset Pompe Disease
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced positive interim safety data from FORTIS Study. The Phase I/II clinical…
Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease
TOKYO, Feb. 7, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…
Astellas Pharma reports 9M results
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement
Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company Initial…
Overactive Bladder Market Spotlight Report 2021: Astellas has the Highest Number of Completed Clinical Trials with 176 Trials
DUBLIN, Jan. 28, 2022 /PRNewswire/ -- The "Market Spotlight: Overactive Bladder" report has been added to ResearchAndMarkets.coms offering. Overactive bladder…
Biotech - Basilea erzielt mit Cresemba-Umsätzen Meilensteinzahlung von 15 Mio Franken
Das Biopharmaunternehmen Basilea hat vom US-Partners Astellas Pharma eine Meilensteinzahlung in Höhe von 15 Millionen Franken erhalten....…
Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea
Ad hoc announcement pursuant to Art. 53 LR...…
Starke Cresemba® (Isavuconazol) Umsätze von Astellas in den USA lösen CHF 15 Mio. Meilensteinzahlung an Basilea aus
Ad hoc-Mitteilung gemäss Art. 53 KR...…
Leuprolide Acetate Market to Record 10.42% Y-O-Y Growth Rate in 2022 |Evolving Opportunities with AbbVie Inc. & Astellas Pharma Inc. | 17000+ Technavio Reports
NEW YORK, Jan. 3, 2022 /PRNewswire/ -- Technavios latest research report on the Leuprolide Acetate Market offers a comprehensive analysis…
Worldwide TIGIT Inhibitor Industry - Featuring Acrus Biosciences, Astellas Pharma and AstraZeneca Among Others
DUBLIN, Dec. 20, 2021 /PRNewswire/ -- The "Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022" report has been…
Astellas, Seagen Announce Positive CHMP Opinion For PADCEV
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) said the CHMP of the European Medicines Agency…
Astellas Pharma, Seagen Get CHMP Positive Opinion for Padcev
Astellas Pharma, Seagen Get CHMP Positive Opinion for Padcev...…
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash., Dec. 17, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas")…
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY).
read more...…
Astellas, Dyno Therapeutics To Develop AAV Gene Therapy Vectors For Skeletal And Cardiac Muscle
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) and Dyno Therapeutics Inc. said that they have reach an agreement to…
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
TOKYO and CAMBRIDGE, Mass, Dec. 1, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,…
Interstitial Cystitis Drugs Market to Grow by USD 283.95 mn from 2020 to 2025| Astellas Pharma Inc. and Bayer AG among Key Vendors | Technavio
NEW YORK, Nov. 17, 2021 /PRNewswire/ -- The interstitial cystitis drugs market is expected to grow by USD 283.95 mn…
NCCN Announces Funding for Prostate Cancer Research Projects, in Collaboration with Pfizer and Astellas
PLYMOUTH MEETING, Pa., Nov. 4, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced…
Astellas Pharma Inc. 2021 Q2 - Results - Earnings Call Presentation
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…